Latest news with #JohnShannon
Time of India
2 days ago
- Sport
- Time of India
"He wants to win the Cup": Connor McDavid might be planning something unexpected in his new contract with the Edmonton Oilers NHL insider hints
Connor McDavid is fully focused on winning the Stanley Cup in the next season.(Image via Sergei Belski-Imagn Images) Connor McDavid , the star player of the Edmonton Oilers, might have faced a heartbreaking loss two months ago when he lost out on the Stanley Cup but the Oilers' captain is in no mood to leave his team. After the Edmonton Oilers lost the Stanley Cup against the Florida Panthers for the second consecutive year, there were many speculations about Connor McDavid exiting the team as his contract expires at the end of the 2025-26 season. But now, it seems the Oilers' captain might just take a pay cut for his team. Connor McDavid might just take a pay cut to focus on winning the Stanley Cup for the Edmonton Oilers, NHL insider reveals A few days ago, NHL insider John Shannon appeared on the Oilers Now, where he spoke to Bob Stauffer about what Connor McDavid might be considering for his new deal with the Edmonton Oilers. NHL insider John Shannon said, 'I think it's a three or four-year deal…I think Connor is entitled to 20 percent, what does that put it at, 17 or 18 (million)?' But it is the reason behind such a potential decision that proves how much Connor McDavid cares about his team, the Edmonton Oilers. NHL insider John Shannon added, 'Connor is also smart enough to know that if he gets too much, that's less to acquire free agents and other players for this hockey club…That's what superstars do, who want to win the Stanley Cup.' John Shannon continued, 'I think Connor's going to come in lower than a lot of people (think).' However, neither Connor McDavid nor his team, the Edmonton Oilers, have confirmed these speculations yet and have remained silent amid all the rumours. What has Connor McDavid been up to in the offseason? While Connor McDavid generally maintains a low profile and prefers to spend time with his family during the offseason, he was recently spotted along with his wife, Lauren Kyle, at his teammate and long time friend, Leon Draisaitl's lavish wedding in Italy. Leon Draisaitl recently tied the knot with actress, Celeste Desjardins, and it seems both Connor McDavid and his wife, Lauren Kyle, had the time of their lives at the wedding. For now, it seems Connor McDavid's focus is on winning the Stanley Cup for the Edmonton Oilers' next season. Also Read: Lane Hutson extension: Why Noah Dobson isn't the right comparable Catch Rani Rampal's inspiring story on Game On, Episode 4. Watch Here!
Time of India
16-07-2025
- Sport
- Time of India
'I do not see it, period': John Shannon rules out Sidney Crosby trade
Photo by Joe Sargent/NHLI via Getty Images Veteran NHL analyst John Shannon has weighed in firmly on the swirling trade rumors involving Pittsburgh Penguins captain Sidney Crosby. Appearing on the Sekeres & Price podcast, Shannon made his stance crystal clear: he does not believe a Crosby trade is on the table. As speculation grows around the Penguins' future, Shannon's words carry significant weight. John Shannon shuts down Sidney Crosby trade talk on Sekeres & Price When asked directly about the possibility of Sidney Crosby being traded, John Shannon responded unequivocally: 'I do not see it, period.' His strong denial came during Episode of the Sekeres & Price podcast, a trusted source for NHL commentary. The veteran broadcaster and former Hockey Night in Canada executive emphasized that despite ongoing rumors, there is no realistic scenario where Crosby is moved. Shannon's dismissal of the trade chatter is a major statement given the growing uncertainty in Pittsburgh. With the Penguins missing the playoffs for a second straight year and entering a transitional phase, many speculated that the franchise might part ways with its longtime captain to begin a full rebuild. But according to Shannon, that's simply not happening. John Shannon: Canucks business continuing deep into the summer. Would Crosby ever leave Pittsburg? Rumors swirl amid Penguins' declining playoff hopes Trade speculation has picked up steam this offseason, fueled by the Penguins' recent struggles and Crosby's age, he is turning 38 this year. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Premium Dubai Homes Now Available—Direct from Dubai's top developer Binghatti Developers FZE Contact Us Undo Reports from multiple outlets have linked him to potential suitors such as the Montreal Canadiens and Colorado Avalanche. Some insiders even suggested that Crosby could waive his no-move clause if the Penguins were fully rebuilding. However, team executives have consistently denied those claims. Both Crosby's camp and the organization have remained quiet, preferring to let speculation play out in the media. Shannon's authoritative voice, though, offers a reality check for those expecting a blockbuster move. A legend likely to stay in Pittsburgh Crosby has spent his entire NHL career with the Pittsburgh Penguins since being drafted first overall in 2005. He's won three Stanley Cups and remains the face of the franchise. While changes could come to the team's roster, it appears Crosby will stay put. John Shannon's strong words provide a firm rebuttal to Sidney Crosby trade rumors. As the offseason progresses, fans and analysts may continue to speculate, but for now, it seems clear: Crosby isn't going anywhere. Also Read: Carter Bear inks entry-level deal with Detroit Red Wings after strong WHL season Catch Rani Rampal's inspiring story on Game On, Episode 4. Watch Here!
Belfast Telegraph
04-07-2025
- General
- Belfast Telegraph
Heroic NI firefighter who pulled driver from burning car seconds before it exploded to receive one of UK's highest bravery honours
John Shannon from Larne was off duty and on his way home from Ballymena Fire Station on the evening of May 5 last year when he came across a three-vehicle pile-up. One vehicle was on fire with an unconscious man trapped inside. Three other passengers were wounded but walking. Mr Shannon saw the fire spreading toward the car's fuel tank and, without any equipment, took immediate action to rescue the unconscious man. Despite the risk of explosion, he approached the burning vehicle, reached inside to undo the driver's seatbelt, and dragged him 20 metres up the road to safety. A police officer arrived at the scene and began assisting Mr Shannon when the car suddenly exploded. By that time, they had moved to a safe distance. The two provided initial treatment at the roadside before the man was taken to hospital. Praising Mr Shannon for his bravery, Andrew Chapman, Secretary of the Royal Humane Society said: 'What he did was incredibly brave. 'As a firefighter he knew better than others the dangers of going near a vehicle that is on fire, but his only thought was to save the man who was unconscious and trapped inside. 'As he was freeing the man and pulling him to safety there was a real danger that the fire could have reached the petrol tank and the vehicle would explode with him reaching inside it. "The reality off that risk can be seen in that it did explode a short time after the man had been pulled to safety. 'Mr Shannon was a true hero and richly deserves the our Bronze Medal which is one of the highest awards we make.' The roots of the Royal Humane Society stretch back nearly 250 years. Other than awards made by the Crown it is the premier national body for honouring bravery in the saving of human life. Founded in 1774 by leading medical figures William Hawes and Thomas Cogan, the organisation was established to promote life-saving resuscitation techniques – an innovative focus at the time. Over the years, the organisation's focus expanded beyond resuscitation, introducing an honours system to recognise acts of bravery in saving lives. The Society also awards non-health care professionals who perform a successful resuscitation. Since it was set up the Society has considered over 90,000 cases and made over 220,000 awards. The Society is a registered charity which receives no public funding and is dependent on voluntary donations.
Associated Press
03-06-2025
- Business
- Associated Press
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Jun 3, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. 'We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients,' said John Shannon, Chief Executive Officer. Path to Long Term Value Creation Financial Guidance & Long-range Outlook 2025 Analyst and Investor Day Event Details The Company's first in-person and virtual analyst and investor day will be in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EDT. To access the live webcast of the event, please use this link: A replay of the webcast, along with the related presentation materials, will be available on the 'Events & Presentations' section of the Company's Investor Relations website following the conclusion of the event. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding financial guidance for 2025, including its expected total revenue and commitment to remaining adjusted EBITDA positive, the outlook for 2030 and outlook for 2035 and beyond, including statements regarding total revenue, product growth, annual net revenue expected for Recorlev® and XP-8121, the market and therapeutic potential of its products and product candidates, including Recorlev and XP-8121, the ability to continue to demonstrate rapid revenue growth, sustained momentum across the portfolio and maintain disciplined execution of the Company's growth strategy, the beneficial impact on the lives of patients, including XP-8121's potential to transform the treatment landscape for millions living with hypothyroidism, capital management enabling the self-funding of both near and long-term growth, and other statements containing the words 'will,' 'would,' 'continue,' 'expect,' 'should,' 'anticipate,' 'new,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators' ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. View source version on CONTACT: Xeris Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications [email protected] KEYWORD: ILLINOIS NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH MANAGED CARE GENERAL HEALTH PHARMACEUTICAL MEDICAL DEVICES CLINICAL TRIALS SCIENCE BIOTECHNOLOGY MEDICAL SUPPLIES OTHER SCIENCE HEALTH SOURCE: Xeris Biopharma Holdings, Inc. Copyright Business Wire 2025. PUB: 06/03/2025 07:30 AM/DISC: 06/03/2025 07:31 AM
Business Wire
03-06-2025
- Business
- Business Wire
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. 'We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to share our vision for the future—one that builds on our successes, leverages our capabilities, and propels us toward making an even greater impact delivering meaningful solutions for patients," said John Shannon, Chief Executive Officer. Path to Long Term Value Creation Proven track record of strong execution — successfully developed and launched a portfolio of products that address unmet medical needs. Recorlev® revenue acceleration has propelled Xeris to a pivotal inflection point, marking a new phase of expected growth. Financial strength enables self-funding of near- and long-term growth — driven by rapid revenue growth and disciplined capital management. XP-8121 has the potential to transform the treatment landscape for millions living with hypothyroidism, reinforcing the Company's commitment to innovation. Financial Guidance & Long-range Outlook 2025 Guidance: The Company reaffirms total revenue in the range of $260 to $275 million and its commitment to remaining adjusted EBITDA positive going forward. 2030 Outlook: The Company expects total revenue of approximately $750 million, reflecting growth across our current portfolio of products, with Recorlev® leading the way. 2035 Outlook & Beyond: The Company anticipates Recorlev® annual net revenue of approximately $1 billion in 2035. XP-8121 peak net revenue is expected to be $1 to $3 billion. 2025 Analyst and Investor Day Event Details The Company's first in-person and virtual analyst and investor day will be in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EDT. To access the live webcast of the event, please use this link: A replay of the webcast, along with the related presentation materials, will be available on the "Events & Presentations" section of the Company's Investor Relations website following the conclusion of the event. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including statements regarding financial guidance for 2025, including its expected total revenue and commitment to remaining adjusted EBITDA positive, the outlook for 2030 and outlook for 2035 and beyond, including statements regarding total revenue, product growth, annual net revenue expected for Recorlev® and XP-8121, the market and therapeutic potential of its products and product candidates, including Recorlev and XP-8121, the ability to continue to demonstrate rapid revenue growth, sustained momentum across the portfolio and maintain disciplined execution of the Company's growth strategy, the beneficial impact on the lives of patients, including XP-8121's potential to transform the treatment landscape for millions living with hypothyroidism, capital management enabling the self-funding of both near and long-term growth, and other statements containing the words 'will,' 'would,' 'continue,' 'expect,' 'should,' 'anticipate,' 'new,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris' experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris' actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its collaborators' ability to protect its intellectual property and proprietary technology, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs, and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris' filings, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
